Skip to main content
Premium Trial:

Request an Annual Quote

Biocius to Move to Larger Facility

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biocius Life Sciences said today that it has reached a new lease agreement and plans to move into a new corporate headquarters in Wakefield, Mass., in June.

The move from the company's current home in Woburn, Mass., will result in a doubling of its capacity, which the company said is necessary due to increased demand for its RapidFire mass spectrometry product and service offerings.

The new facility, which is located around five miles from the firm's current one and will include an enhanced laboratory and a seminar and training room, will increase the company's contract research screening capabilities by around 50 percent, it said.

"Biocius has started on a growth trajectory and the new facility provides an environment to accommodate our expansion plans," Biocius CEO Jeffrey Leathe said in a statement.

Financial terms of the lease agreement were not released.

The company was formed as a spin-out from Biotrove when that firm was acquired by Life Technologies in late 2009.

The agreement gave Biocius all of Biotrove's intellectual property related to its RapidFire platform, and the employees working at Biotrove with the RapidFire line moved on to Biocius after the acquisition.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.